DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Goldman Sachs Downgrades Vir Biotechnology to Neutral

Goldman Sachs analyst Paul Choi downgrades Vir Biotechnology (NASDAQ:VIR) from Buy to Neutral.

Benzinga · 03/13/2020 09:28

Goldman Sachs analyst Paul Choi downgrades Vir Biotechnology (NASDAQ:VIR) from Buy to Neutral.